Chidamide and linperlisib for relapsed follicular lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of two oral drugs, chidamide and linperlisib, for people with follicular lymphoma that has not responded to or come back after at least two prior treatments. The goal is to see if this combination can help shrink the lymphoma and stop it from growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have follicular lymphoma (grades 1, 2, or 3a) and it has come back or not responded after at least two prior treatments
- At least one of your past treatments included an anti-CD20 antibody (e.g., rituximab)
- You are 18 or older and in reasonably good health (able to care for yourself, ECOG 0-2)
- You have a tumor that can be measured on a CT or MRI scan (lymph node >1.5 cm or other lesion >1 cm)
- Your blood counts and liver/kidney function are within acceptable ranges (neutrophils ≥1.5, hemoglobin ≥8, platelets ≥75, etc.)
- You have not taken certain PI3K inhibitors before and had your lymphoma worsen during or soon after treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs, Chidamide and Duvalisib, for people with peripheral T-cell lymphoma or NK/T-cell lymphoma that has come back or not responded to previous treatment. The goal is to see if this drug combination can help shrink or control the lymphoma.
This trial tests a combination of two drugs, linperlisib and chidamide, for people whose peripheral T-cell lymphoma has come back or not responded to at least one prior treatment. The goal is to see if this combination can shrink or control the lymphoma.
This trial tests two pills—linperlisib and chidamide—for people with a type of lymphoma called PTCL. The combination might work better together than either alone.
This trial tests a combination of drugs (linperlisib, cyclophosphamide, prednisone, and thalidomide) for people with certain types of non-Hodgkin lymphoma that have come back or not responded to previous treatments. It aims to see if this combination can help control the disease.
This trial tests a drug called linperlisib combined with standard chemotherapy and immunotherapy for people with large B-cell lymphoma that has come back or not responded to one prior treatment.
This trial tests a combination of two drugs, linperlisib (a PI3K inhibitor) and rituximab, for people whose indolent (slow-growing) non-Hodgkin lymphoma has come back or stopped responding to treatment. It aims to see if adding linperlisib to rituximab can help shrink tumors.
Hear when a new Follicular Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.